- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI Summary - About
Freenome, Inc. Common stock(FRNM)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Advisory Performance History (Simulated)
Upturn Advisory & Investor View for FRNM
11/13/2026: FRNM (1-star) is currently NOT-A-BUY. Pass it for now.
Freenome is a commercial-stage diagnostic company developing blood-based early cancer screening tests through an AI-powered multiomics platform. The company's primary strengths include its validated technology and an exclusive U.S. commercialization partnership with Abbott for its lead test, SimpleScreen CRC. Its core growth story centers on scaling non-invasive cancer screening adoption and expanding its portfolio into indications like lung cancer. Key risks include heavy reliance on commercial partners, intense competition in liquid biopsy, and ongoing net operating losses. The stock suits growth-oriented investors willing to accept volatility while monitoring commercial rollout milestones and reimbursement progress.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Strong fit | Freenome offers high-growth potential driven by the commercial scaling of its innovative early cancer detection blood tests. |
| Momentum investor | Strong fit while signal remains positive | Momentum appeal depends on positive market reactions to ongoing clinical data readouts and commercial rollout milestones. |
| Value investor | Weak fit | The company is a development-stage diagnostics provider currently generating operating losses as it scales commercial operations. |
| Dividend investor | Weak fit | Freenome does not pay dividends, retaining all capital for clinical growth and product commercialization. |
| Low-risk investor | Weak fit | Early-stage biotechnology and diagnostic stocks carry elevated clinical, regulatory, and market execution volatility risks. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | Post-IPO stock prices can fluctuate significantly based on commercial adoption updates and market sentiment. |
| Valuation risk | Medium / high | Valuations rely heavily on long-term adoption projections for early cancer screening products. |
| Competition risk (AI/multiomics and liquid biopsy competition) | High | Freenome competes with well-funded diagnostics giants like Guardant Health and GRAIL. |
| Business quality | Medium | Proprietary multiomics technology is robust, but commercial infrastructure is still maturing. |
| Dividend income | Low / none | No dividend distributions are provided to investors. |
| Execution risk | High | Success depends heavily on commercial execution partner Abbott and physician test adoption. |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.16B USD | Price to earnings Ratio - | 1Y Target Price 18 |
Price to earnings Ratio - | 1Y Target Price 18 | ||
Volume (30-day avg) 801.2K shares | Beta 0.6 | 52 Weeks Range 9.71 - 17.50 | Updated Date 11/15/2026 |
52 Weeks Range 9.71 - 17.50 | Updated Date 11/15/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.04 |
Sector & Industry Intelligence
Sector
Healthcare
Bullish- Sentiment
- Strong Bullish
- Momentum
- Momentum Steady
- BUY participation
- 62.6%
- Active BUY / eligible
- 72 / 115
- 30-Day BUY Count Change
- +35
- Market state
- Strong Bullish
The number of qualifying BUY stocks has remained relatively stable.
Industry
Diagnostics & Research
- BUY participation
- 68.8%
- Active BUY / eligible
- 11 / 16
- 30-Day BUY Count Change
- 0
Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.
Price Behavior

Insufficient Data
The stock demonstrates a Insufficient Data price path pattern.

Insufficient Data
The stock price exhibits a Insufficient Data stability pattern.
Analysis of Past Performance
Type Stock | Historic Profit -6.02% | Avg. Invested days 39 | Today’s Advisory PASS |
Upturn Advisory Rating ![]() | Upturn Advisory Performance | Stock Returns Performance |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals 
Financial Health Rating 
Growth Momentum Score 
Ownership 
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue) 
Economic Dimensions
Quantitative Style Profile 
Style Classification
Quality Focused
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Personalized Cancer Detection (PCD) Commercialization | Revenue generated from commercialized blood-based screening tests such as SimpleScreen CRC through distribution partners. | The primary long-term engine driving product sales and market adoption. |
| Collaborations and License Agreements | Milestone payments and collaboration fees derived from partnerships with major healthcare companies like Abbott. | Provides non-dilutive financial support and commercial validation during early market entry. |
Earnings Date
Report Date 2026-11-10 | When After Market | Estimate - | Actual 1.1 |
Profitability
Profit Margin -50.83% | Operating Margin (TTM) -43.81% |
Management Effectiveness
Return on Assets (TTM) -10.36% | Return on Equity (TTM) -35.9% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 932.41M | Price to Sales(TTM) 5.33 |
Enterprise Value 932.41M | Price to Sales(TTM) 5.33 | ||
Enterprise Value to Revenue 30.66 | Enterprise Value to EBITDA - | Shares Outstanding 111.50M | Shares Floating 51.37M |
Shares Outstanding 111.50M | Shares Floating 51.37M | ||
Percent Insiders 27.26 | Percent Institutions 51.1 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.

